ClinicalTrials.gg
Not yet recruitingNCT07516639Updated Apr 13, 2026

First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

A Phase 1 interventional study of ISH0613 for injection and Placebo in Healthy Subjects (HS) and SLE (Systemic Lupus), sponsored by SUNHO(China)BioPharmaceutical CO., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by SUNHO(China)BioPharmaceutical CO., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
142nd of 245
26 · median 36
Started
2026
with 55 others
Phase 1
109 of 266
85 open now
Primary completion
2026-12
later than 72 of 190 live
Registered
243rd of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 142nd largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 109 in phase 1, reaches primary completion later than 72 of the 190 other live ones, and was the 243rd registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about a study drug called ISH0613 and how it behaves in healthy adults.

This study will also evaluate the safety and tolerability of ISH0613 after a single intravenous (IV) dose.

The main questions this study aims to answer are:

I. What medical problems (side effects) may occur after receiving ISH0613? How does ISH0613 move through and get processed in the body? II. Does ISH0613 affect certain biological markers related to the immune system? III. Researchers will compare ISH0613 to a placebo (a look-alike substance that contains no active drug) to better understand its effects.

Participants will:

I. Receive a single intravenous infusion of either ISH0613 or placebo II. Stay in the clinical unit for several days for close monitoring after dosing III. Return to the clinic for follow-up visits over several weeks IV. Provide blood samples for safety checks and laboratory testing V. Be monitored for any side effects throughout the study

03

Conditions studied

  • Healthy Subjects (HS)
  • SLE (Systemic Lupus)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Chinese adult subjects, male or female, aged 18 to 45 years (inclusive);
  2. (BMI) between 19.0 and 28.0 kg/m² (inclusive); body weight generally ≥50 kg for males and ≥45 kg for females;
  3. Male subjects and their partners, or female subjects, must agree to use at least one effective non-pharmacological method (e.g., complete abstinence, intrauterine device, partner sterilization) during the study period, and must have no plan for sperm or egg donation;
  4. Subjects are able to fully understand the purpose, nature, and procedures of the study, including potential adverse reactions, and voluntarily sign the form (ICF);
  5. Subjects are able to communicate well with the investigator and are willing and able to comply with all study procedures and requirements.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to the product or any of its , or a history of to monoclonal antibodies;
  2. History or presence of diseases of the cardiovascular, endocrine, nervous, gastrointestinal, respiratory, genitourinary, hematological, immunological, psychiatric, or metabolic systems, or any other condition that may interfere with study results, as judged by the investigator;
  3. Clinically significant abnormalities in laboratory tests (hematology, urinalysis, biochemistry, coagulation) or auxiliary examinations (chest X-ray, abdominal ultrasound);
  4. Positive test results for surface antigen (HBsAg), virus antibody (HCV-Ab), (HIV) antibody, or syphilis antibody;
  5. Receipt of any surgical procedure within 6 months prior to signing the form, or planned surgery (including cosmetic, dental, or oral surgery) within 2 weeks after the end of the study;
  6. Alcohol consumption exceeding 14 units per week within 3 months prior to screening (1 unit = 360 mL beer, 150 mL wine, or 45 mL liquor), or positive alcohol breath test at screening or baseline, or inability to abstain from alcohol during the study;
  7. Average smoking of more than 5 cigarettes per day within 3 months prior to screening;
  8. History of drug abuse, use of soft drugs (e.g., cannabis) within 3 months prior to screening, or use of hard drugs (e.g., cocaine, phencyclidine) within 1 year prior to screening, or positive drug abuse screening test (including morphine, ketamine, THC-COOH, methamphetamine, MDMA, cocaine);
  9. Habitual excessive intake within 4 weeks prior to screening of caffeine-containing beverages or foods or substances that may affect drug metabolism, such as coffee (>1100 mL/day), tea (>2200 mL/day), cola (>2200 mL/day), energy drinks (>1100 mL/day), or chocolate (>510 g/day);
  10. Use of any prescription drugs, over-the-counter medications, or traditional Chinese medicines within 14 days prior to dosing;
  11. Receipt of any monoclonal antibody therapy within 6 months prior to dosing;
  12. Vaccination within 3 months prior to dosing, or planned vaccination during the study period;
  13. Participation in another clinical trial and receipt of investigational drug treatment within 3 months prior to dosing;
  14. Blood donation or significant blood loss (>400 mL, excluding menstrual loss) within 3 months prior to screening, or receipt of blood transfusion or blood products, or planned blood donation during the study period or within 1 month after study completion;
  15. Pregnant or lactating women;
  16. Clinically significant abnormal vital signs (systolic blood pressure \<90 mmHg or ≥140 mmHg; diastolic blood pressure \<55 mmHg or ≥90 mmHg; heart rate \<50 bpm or >100 bpm; body temperature \<35.4°C or >37.3°C), or clinically significant abnormalities ( >450 ms for males, >470 ms for females), or clinically significant findings on physical examination, as judged by the investigator;
  17. Presence of infection requiring treatment for acute or chronic infection, including but not limited to:

    1. Herpes zoster within 12 months prior to screening;
    2. Current suppressive therapy for chronic infections (e.g., tuberculosis, Pneumocystis, cytomegalovirus, herpes simplex virus, varicella-zoster virus, or atypical mycobacteria);
    3. History of tuberculosis or contact with active tuberculosis within 6 months prior to screening, or positive T-SPOT test;
    4. Parasitic infection within 3 months prior to dosing;
    5. Hospitalization due to infectious disease within 30 days prior to dosing;
    6. Parenteral anti-infective treatment (including antibacterial, antiviral, antifungal, or antiparasitic agents) within 30 days prior to dosing;
  18. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Single-ascending dose:ISH0613

    Drug: ISH0613 for injection

  • Placebo comparator
    Single-ascending dose:Placebo

    Drug: Placebo

Interventions

  • DrugISH0613 for injection

    80, 240, 480, 640 mg; i.v.

  • DrugPlacebo

    80, 240, 480, 640 mg; i.v.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events as assessed by CTCAE v6.0

    Time frame: baseline through day 57

  2. Injection site reactions assessments

    Time frame: baseline through day 57

Secondary outcomes

  1. Maximum observed serum concentration (Cmax)

    Time frame: baseline through day 57

  2. Time to reach maximum observed serum concentration (Tmax)

    Time frame: baseline through day 57

  3. AUC from time 0 to the time of the dosing interval (AUC0-t)

    Time frame: baseline through day 57

  4. AUC from time 0 to infinity (AUC₀-∞)

    Time frame: baseline through day 57

  5. Terminal elimination half-life (t1/2)

    Time frame: baseline through day 57

  6. Apparent clearance after extravascular administration (CL/F)

    Time frame: baseline through day 57

  7. Apparent volume of distribution during the terminal elimination phase after extravascular administration (Vd/F)

    Time frame: baseline through day 57

  8. Serum immunoglobulin levels (IgG, IgA, IgM)

    Time frame: baseline through day 57

  9. B cell count

    Time frame: baseline through day 57

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 8 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 8, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07516639
Lead sponsor
SUNHO(China)BioPharmaceutical CO., Ltd.
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Ya Ze Jiao
Contact
15950520087@163.com
15950520087

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion